FOI 22/1224 – Amiloride Rosemont, Overviews, clinical-nonclinical

REQUEST

15 December 2022

I should be grateful if you could provide me with copies of the Clinical and the Nonclinical overview for the following product:

MA name: Amiloride Rosemont 5mg/5ml Oral Solution

MA Number: PL 00427/0091

MAH: Rosemont Pharmaceuticals Ltd

MHRA RESPONSE

31 January 2023

Regarding your request, we have searched our records (including the database that corresponds to our archived paper records), for the Amiloride Rosemont 5mg/5ml Oral Solution document/s you refer to. However, we have been unable to locate these documents. Therefore, having exhausted all the usual avenues, we must conclude that we do not hold this information.

If you have a query about the information provided, please reply to this email

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date you receive this response and addressed to: <u>info@mhra.gov.uk</u>

If you remain dissatisfied following any internal review, you may ask the Information Commissioner (ICO) to decide on whether or not we have interpreted the FOIA correctly in dealing with the request and subsequent internal review. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The ICO's address is:

The Information Commissioner's Office Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF

Yours sincerely

MHRA Customer Service Centre

Medicines and Healthcare products Regulatory Agency 10 South Colonnade, Canary Wharf, London E14 4PU